Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07427797 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
A Phase 3 study of Moderate to Severe Glabellar Lines, sponsored by Ipsen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT07427797: Recruiting Phase 3 study of Moderate to Severe Glabellar Lines, sponsored by Ipsen.
NCT07427797 is a Phase 3 study of Moderate to Severe Glabellar Lines that is actively recruiting participants, run by Ipsen. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07427797, a Phase 3 study of Moderate to Severe Glabellar Lines, is actively recruiting participants, sponsored by Ipsen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the effectiveness and safety of IPN10200 compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence. In this study, all participants will receive a single injection of either IPN10200 or placebo (the study drug). There will be 3 periods in this study: * A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre. * A treatment period (Day 1) where all the eligible participants will receive a single injection of IPN10200 or placebo. * A follow-up period (52 weeks) where participants' health will be monitored, consisting of regular visits to the study centre and 1 telephone call visit. Participants will undergo health measurements and observation, including blood sampling, physical examinations, clinical evaluations and electrocardiograms (ECG: recording of the electrical activity of heart). They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 55 weeks. Participants may withdraw consent to participate at any time.
Primary Outcome
Measured by the multicomponent response of ≥2-grade improvement from baseline and a score of 'None' or 'Mild' on Investigator's Live Assessment (ILA) and Subject's Self-Assessment (SSA) at maximum frown ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe." SSA: a 4-point categorical scale used to assess the appearance of glabellar lines a
Conditions Studied
Interventions
- BIOLOGICAL IPN10200
- BIOLOGICAL Placebo
Study Locations (20)
California
- Ablon Skin Institute and Research Center - Manhattan Beach
- Keith A. Marcus, MD Inc - Redondo Beach
- West Dermatology - San Diego
- Ava T. Shamban, M.D., Inc. - Santa Monica
- Art of Skin MD - Solana Beach
- Pacific Clinical Innovations Inc. - Vista
Arizona
- Advanced Research Associates - Glendale
- Avacare - Scottsdale
- Investigate MD, LLC - Scottsdale
Texas
- Westlake Dermatology & Cosmetic Surgery - Westlake - Austin
- Dermatology and Laser Surgery Center - Houston
- Pflugerville Dermatology Clinical Research Center, Inc. d/b/a Austin Institute for Clinical Research - Pflugerville
British Columbia
- Carruthers and Humphrey Cosmetic Medicine - Vancouver
- Pacific Dermaesthetics Inc. - Vancouver
Alabama
- Skin Wellness Dermatology - Homewood - Birmingham
Florida
- Skin Research Institute - Coral Gables
Maryland
- ICON Dermatology and Aesthetics - Bethesda
South Carolina
- Clinical Research Center of the Carolinas - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-02-27 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 3 |
What NCT07427797 shows while recruiting
NCT07427797 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Moderate to Severe Glabellar Lines appearing as the primary indexed condition, and to 2 interventions - of which IPN10200 is the first listed.
NCT07427797 names 20 study sites across 10 states, led by California, Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT07427797 about?
NCT07427797 is a clinical study titled "A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows". The purpose of this study is to assess the effectiveness and safety of IPN10200 compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable...
What is the current status of trial NCT07427797?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-02-27. Estimated completion is 2027-07-15.
What conditions does trial NCT07427797 study?
This clinical trial studies the following conditions: Moderate to Severe Glabellar Lines.
What interventions are being tested in trial NCT07427797?
The interventions under investigation include: IPN10200 (BIOLOGICAL), Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT07427797?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07427797 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Glabellar Lines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07427797's enrollment target sits among peer trials
300 1123rd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI